Gleevec scientifically known as CGP57148 (imatinib) and formerly known as STI571 is the new member of a class of agents that act by binding using a kinase inhibitor to try to control CML. It acts as a specific kinase inhibitor, which induces complete remission in the population of those with chronic-phase CML. As a result of the treatment there are no immature cells seen in the blood, and the spleen returns to its normal size in a complete hematologic response (CHR). Equally patients using Gleevec
Chronic Myeloid leukemia (CML) is a blood and bone marrow disease that slowly progresses. The disease usually occurs in middle aged or older individuals and rarely occurs in children. In CML, an unusually high number of blood stem cells become granulocytes. These granulocytes, also called leukemia cells are irregular in shape and do not develop into healthy white blood cells. Eventually, they concentrate in the blood leaving no room for healthy cells which may lead to infection, anemia, or bleeding
intracellular concentrations significantly decreased in the presence of afatinib, bosutinib, gefitinib, imatinib, lapatinib, ponatinib, sunitinib and vandetanib. LLC-PK1 cells do not express OATP-C uptake transporters.(40) Dasatinib uptake studies in MDCK-II wild type cells revealed a slightly different trend. Among the 14 ingredients screened, 6 of them, namely, axitinib, erlotinib, imatinib, lapatinib, nilotinib and pazopanib exhibited a significant increase in dasatinib intracellular concentrations
Animals in research have made many contributions leading to the treatments and cures of diseases that affects humans. Through the use of animals in experiments a better life has been accomplished. “Sweet are the uses of Adversity.” This quote said by Williams Shakespeare proves that all good comes with bad, just like using animals in research. Many oppose the use of animal for research claiming that it is not morally or ethically stable. Findings from animal experiments can potentially cure numerous
the life of patients with stage 4 melanoma. This can cause very severe side effects. It has never been shown to cure melanoma. "A small portion of melanomas have changes in the C-KIT gene. These melanomas might be helped by targeted drugs such as imatinib (Gleevec) and nilotinib (Tasigna), although, again, these drugs are not known to cure these melanomas."(Cancer,
Childhood leukemia is a devastating disease that often leads to death situations. One has to know that Leukemia is not just a word, but also a reality. “Over half of children diagnosed with cancer each year have leukemia” (Ruccione). There are many types of leukemia, but there four main types that appear among minors. Through this research, one will discover the different aspects of this cancer and in knowing this may help understand and learn about Leukemia more. Childhood Leukemia is a blood cancer
1. (10) b. Explain why in multiple sclerosis the action potentials take longer to reach their muscle and neurological targets or do not reach them at all, resulting in muscle spasms and weakness in one or more limbs, bladder dysfunction, local sensory losses, visual disturbances and other neurological deficits. c. Explain the speed of action potential in the normal person. Be sure to provide documentation using any example from the literature (provide the pdf-version of the article) and summary
Oncology: The Painfully Great Science Outline -Introduction -What is Cancer? -What is Oncology? -Rituxan -Avastin -Revlimid -Gleevec -Conclusion Oncology: The Painfully Great Science “When someone has cancer, the whole family and everyone who loves them does, too.” – Terri Clark This statement is very true. When someone is diagnosed with cancer it starts a journey down a road that no one wants to travel on. In recent years, there have been countless trials and tests to find
In fabrication micro-sensors and devices micro-electro-mechanical systems (MEMS) provides significant opportunities, which are borrowed it fabrication abilities from semiconductor technology. Advances in semiconductor technologies since 1970s have paved the way for fabrication of the devices with micron dimensions. These devices were categorized under the MEMS field, which was a combination of mechanical structures with electronic readout circuits. MEMS technology has borrowed its fabrication capabilities